DENVER, Colo., June 4 /PRNewswire-FirstCall/ -- Wyndgate Technologies(R), a division of Global Med Technologies(R), Inc. , today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Donor Doc(TM), paving the way for the Company to proceed to market the product in the United States.
( LOGO: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO )
The Donor Doc release introduces Wyndgate’s new ElDorado suite of integrated blood management solutions and shares key component modules with future products. Donor Doc is the Company’s next-generation software which creates a bridge between Wyndgate’s popular SafeTrace(R) systems and its donor and transfusion software innovations which are nearing completion.
ElDorado Donor Doc is an electronic health history questionnaire and physical exam tracking system which assists blood centers in screening donors by capturing medical and physical examination information. The system allows donors to self-administer questionnaires at an individual’s pace, choosing text or audio presentation of questions in their preferred language, as well as graphics to clarify content.
Donor Doc may be implemented on standard and touch-screen computers allowing maximum flexibility at fixed-site and mobile blood drives. The software identifies donor responses where additional staff investigation is necessary and helps blood centers prevent release of products from unsuitable donors. Donor Doc also provides maximum integration with donor center information systems, including SafeTrace, the Company’s blood center management system.
To assure that Donor Doc would meet client demands for features and performance, Wyndgate organized a technology work group consisting of leading industry representatives from around the world. The group provided guidance during analysis, development and beta testing of Donor Doc, and their contributions assisted the Company in delivering a feature-rich and user friendly solution. The resulting software system streamlines the experience for donors and staff and helps customers to realize efficiencies and cost savings, while improving overall safety.
Thomas F. Marcinek, President and Chief Operating Officer, commented, “We are excited that we can accept orders from customers in the U.S. for this potentially high-demand product now that it has been 510(k) cleared. The Company has made a serious commitment to our customers by continuing to invest in innovations which help them meet their business and regulatory needs.” Mr. Marcinek further commented, “Global Med is dedicated to providing solutions and services that help support and protect the public’s health. We value the trust that our customers place in us, and their continued efforts to improve the safety of the blood supply. We believe that the introduction of this first module of the ElDorado suite will accelerate growth and bring us closer to our goal of becoming a world leader in blood management software and services.”
About Global Med Technologies, Inc.
Global Med Technologies, Inc. is an international e-Health medical information technology company providing information management software products and services to the healthcare industry. Its Wyndgate Technologies division is a leading supplier of information management systems to U.S. and international blood centers and hospital transfusion centers. Each year, Wyndgate’s products and services manage more than eight million blood components, representing over 27% of the U.S. blood supply. Wyndgate’s products are being used in Canada and sub-Saharan Africa, and are being implemented in the Caribbean. Together, the SafeTrace Tx(R)* advanced transfusion management system and the SafeTrace donor management system provide Vein-to-Vein(R) tracking from donor collection to patient transfusion.
For more information about Global Med’s products and services, please call 800-WYNDGATE or visit http://www.globalmedtech.com, http://www.peoplemed.com and http://www.wyndgate.com.
This news release may include statements that constitute forward-looking statements, usually containing the words “believe,” “estimate,” “project,” “expects” or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this news release.
*Patent Pending Company Contact: Investor Contact: Global Med Technologies, Inc. Paul Holm Michael I. Ruxin, M.D. H.L. Lanzet (303) 238-2000 paulmholm@gmail.com (212) 888-4570
Photo: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comGlobal Med Technologies, Inc.
CONTACT: Michael I. Ruxin, M.D. of Global Med Technologies, Inc.,+1-303-238-2000; investors, Paul Holm, paulmholm@gmail.com, or H.L. Lanzet,both of Global Med Technologies, Inc., +1-212-888-4570
